Argatroban for Stroke

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
StrokeArgatroban - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is comparing two different blood clot treatments to see which one results in better outcomes for patients who have had a stroke.

Eligible Conditions
  • Stroke

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Study Objectives

1 Primary · 7 Secondary · Reporting Duration: 2 at 24 hours after randomization

Hour 24
proportion of participants with NIHSS less than or equal to 2 at 24 hours
24 hours after randomization
change from baseline to 24-hour NIHSS
90 days after randomization
90-day EQ-5D
90-day modified Rankin scores (mRS)
90-day ordinal analysis of the mRS
proportion of participants with 90-day mRS 0-1 (or return to their historical mRS)
proportion of participants with 90-day mRS 0-2 (or return to their historical mRS)
baseline
proportion of participants who have thrombectomy

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

3 Treatment Groups

Argatroban
1 of 3
Eptifibatide
1 of 3
Placebo
1 of 3

Experimental Treatment

Non-Treatment Group

1200 Total Participants · 3 Treatment Groups

Primary Treatment: Argatroban · Has Placebo Group · Phase 3

Argatroban
Drug
Experimental Group · 1 Intervention: Argatroban · Intervention Types: Drug
Eptifibatide
Drug
Experimental Group · 1 Intervention: Eptifibatide · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Argatroban
FDA approved
Eptifibatide
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 at 24 hours after randomization

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,805 Previous Clinical Trials
2,277,415 Total Patients Enrolled
22 Trials studying Stroke
76,204 Patients Enrolled for Stroke
National Institute of Neurological Disorders and Stroke (NINDS)NIH
1,261 Previous Clinical Trials
453,762 Total Patients Enrolled
163 Trials studying Stroke
82,145 Patients Enrolled for Stroke
Opeolu Adeoye, MDPrincipal InvestigatorWashington University School of Medicine
1 Previous Clinical Trials
27 Total Patients Enrolled
1 Trials studying Stroke
27 Patients Enrolled for Stroke

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a NIHSS score of 6 or more.

Who else is applying?

What state do they live in?
New York100.0%
What portion of applicants met pre-screening criteria?
Did not meet criteria100.0%